EUCTR2013-000093-29-ES进行中（未招募）1 期
A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. The subject has consented and signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written Informed Consent and privacy language as per national
- •regulations (e.g., Health Insurance Portability and Accountability Act [HIPAA] for U.S. sites) prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).
- •2. The subject is a female ? 18 years of age.
- •3. The subject has histologically or cytologically proven adenocarcinoma of the breast that is HER2+ defined as a score of 3+ for staining by immunohistochemistry (IHC), or IHC 2+ with
- •HER2 gene amplification as determined by a locally approved in situ hybridization (ISH) assay, or (for patients without IHC data) HER2 gene amplification.
- •4. The subject has AR+ and ER- /PgR- breast cancer:
- •a) AR+ breast cancer is defined as any tumor cells with nuclear AR staining by immunohistochemistry (IHC). Enrollment may be based on the local pathologist?s findings; however, tissue will be sent to a central pathology laboratory for assessment.
- •NOTE: If a subject is enrolled in the study based on local pathologist results, but subsequent central assessment cannot confirm AR+ disease, the subject may remain in the study.
- •b) ER-/PgR- breast cancer is defined as < 1% of tumor cells with nuclear ER/PgR staining by immunohistochemistry (IHC) or (for subjects with 1 - <10% tumor cells with nuclear
- •ER/PgR staining by IHC) the investigator would not treat with hormonal therapy (such as an aromatase inhibitor). Enrollment will be based on the local pathologist?s findings.
- •5. The subject has metastatic disease or has locally advanced disease that is not amendable to curative treatment.
- •6. The subject has measurable disease according to RECIST 1.1.
- •7. The subject has received at least 1 but no more than 4 lines of therapy in the metastatic or locally advanced disease (a line of therapy is defined as a course of treatment at the end of
- •which there was disease progression):
- •a) The subject has been documented to have progressed by investigator determination on a regimen containing an approved anti-HER2 agent (includes trastuzumab emtansine in
- •countries where it is not approved) as the most recent regimen. NOTE: Pertuzumab in the most recent regimen is exclusionary.
- •b) The subject progressed on a trastuzumab containing regimen for adjuvant (defined as progression >12 months after completing adjuvant treatment) or metastatic/ locally
- •advanced disease.
- •The subject has adequately recovered from toxicities due to prior therapy.
- •9. The subject has an Eastern Cooperative Oncology Group (ECOG) performance status < 1 at Screening and Day 1.
- •10. The subject has available at the site a representative, formalin-fixed, paraffin-embedded, tumor specimen that enabled the definitive diagnosis of breast cancer with adequate viable tumor
- •cells in a tissue block (preferred) or ? 10 (20 preferred) freshly cut, unstained, serial slides and the associated pathology report:
- •a) Archival tissue from a primary tumor is preferred, but if the specimen is insufficient or unavailable, a core needle or incisional biopsy from a metastatic lesion is acceptable.
- •b) Cytological or fine-needle aspiration samples are not acceptable.
- •11. The subject has an estimated life expectancy of at least 6 months at Day 1, in the opinion of the Investigator.
- •12. The subject is either: Of non-childbearing potential: a) post-menopausal (defined as no spontaneous menses for at least 12 months pr
排除标准
- •1.The subject has a severe concurrent disease, infection, or comorbidity that, in the judgment of the Investigator, would make the subject inappropriate for enrollment.
- •2.The subject has current or previously treated brain metastasis or active leptomeningeal disease.Brain imaging is required during screening in all subjects to exclude the presence of unequivocal central nervous system disease.
- •3.The subject has a history of a non-breast cancer malignancy with the following exceptions:a)The subject with a previous history of a non-invasive carcinoma is eligible if in the opinion of the Investigator he/she has had successful curative treatment any time prior to Screening.b)For all other malignancies, the subject is eligible if they have undergone potentially curative therapy and they have been considered disease free for at least 5 years prior to Screening.
- •4.The subject has inadequate marrow, hepatic, and/or renal function at the Screening Visit defined as: 1)absolute neutrophil count < 1.5 x109/L (< 1500 cells/mm3) 2)Platelet count < 75 x109/L (< 75,000 cells/mm3) 3) Hemoglobin < 5.6 mmol/L (< 9 g/dL) 4) Total bilirubin > 1.5 x Upper Limit of Normal (ULN) unless there is an alternate nonmalignant etiology (e.g., Gilbert?s syndrome). 5) Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x ULN (or >5 xULN if hepatic metastasis is present).6)Creatinine > 1.5 x ULN. NOTE: May not have received any growth factors or blood transfusions within 7 days before the hematology values obtained at screening
- •5.The subject has a history of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma).
- •6.The subject has a history of loss of consciousness, cerebrovascular accident or transient ischemic attack within 12 months before the Day 1 visit.
- •7. The subject has had a hypoglycemic episode requiring medical intervention while on insulin (or other anti-diabetic) treatment within 12 months before Day 1.
- •8.The subject has clinically significant cardiovascular disease including: a) Myocardial infarction within 6 months before the Day 1 visit. b) Uncontrolled angina within 6 months before the Day 1 visit. c) Congestive heart failure New York Heart Association (NYHA) Class III or IV or history of congestive heart failure NYHA Class III or IV in the past, unless a screening echocardiogram or multi-gated acquisition scan performed within 3 months before the Day 1 visit reveals a left ventricular ejection fraction that is ? 50%. d)History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, Torsade de Pointes).e) History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place. f) Hypotension as indicated by systolic blood pressure < 86 mmHg on 2 consecutive measurements at the Screening visit. g) Bradycardia (in the presence of known cardiovascular disease) as indicated by a heart rate of < 50 beats per minute on the Screening electrocardiogram (ECG) recording. h) Uncontrolled hypertension as indicated by systolic blood pressure > 170 mmHg or diastolic blood pressure > 105 mmHg on 2 consecutive measurements at the Screening visit.
- •9. The subject has significant respiratory disease, including severe dyspnea at rest due to complications of advanced malignancy or requiring supplementary oxygen therapy.
- •10. The subject has an active gastrointestinal disorder affecting absorption (e.g., gastrectom
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to evaluate if apremilast is safe in children and adolescents with moderate to severe plaque psoriasis as well as assessing how apremilast is processed by the body, and to determine the appropriate dose for themModerate to severe plaque psoriasis in adolescents (ages 12 to 17 years, inclusive) and in children (ages 6 to 11 years, inclusive).MedDRA version: 18.1 Level: LLT Classification code 10071117 Term: Plaque psoriasis System Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 18.1 Level: PT Classification code 10037153 Term: Psoriasis System Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2015-003314-24-ESCelgene Corporation32
进行中（未招募）
不适用
A Phase 2, Multicenter, Open-label Study to Assess the Safety and Tolerability of OralOPC-34712 as Monotherapy in Adult Patients with SchizophreniaMedDRA version: 12.0Level: LLTClassification code 10039626Term: SchizophreniaschizophreniaEUCTR2009-012568-14-SKOtsuka Pharmaceutical Development & Commercialization300
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of of Enzalutamide with Trastuzumab in patients with HER2+ AR+ Metastatic or Locally Advanced Breast CancerSubjects with HER2+ AR+ Metastatic or Locally Advanced Breast CancerMedDRA version: 20.0Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000093-29-GBAstellas Pharma Global Development, Inc.80
已完成
2 期
An open label study to assess safety and tolerability of OPC-34712 in patients with schizophrenia.CTRI/2009/091/000953Otsuka Pharmaceutical Development Commercialization300
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of of Enzalutamide with Trastuzumab in patients with HER2+ AR+ Metastatic or Locally Advanced Breast CancerEUCTR2013-000093-29-BEAstellas Pharma Global Development, Inc.80